摘要
目的:评价国产利福昔明与环丙沙星治疗细菌性肠道感染的成本-效果。方法:采用循证医学方法收集国产利福昔明与环丙沙星治疗细菌性肠道感染的临床资料,应用药物经济学的最小成本分析法及成本-效果分析法进行分析。结果:国产利福昔明与环丙沙星治疗细菌性肠道感染有效率分别为97.14%(746/768)、97.19%(761/783)(P>O.05);成本-效果比分别为151与9.25。结论:环丙沙星治疗细菌性肠道感染更经济。
OBJECTIVE： To evaluate the cost- effectiveness of rifaximin vs. ciprofloxacin in the treatment of bacterial intestinal infection. METHODS： The clinical data of rifaximin and eiprofloxacin in the treatment of bacterial intestinal infection were collected by evidence - based medicine method, which were analyzed using cost - minimization analysis and cost- effectiveness analysis in pharmacoeconomics. RESULTS： The effective rates of rifaximin and ciprofloxacin in the treatment of bacterial intestinal infection were 97.14% （746/768）and 97.19% （761/783） （ P 〉 0.05）, respectively, and the cost- effectiveness ratios were 151 and 9.25, respectively. CONCLUSION： Ciprofloxacin is more economical than rlfaximin in the treatment of bacterial intestinal infection.
出处
《中国医院用药评价与分析》
2009年第9期689-690,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
循证医学
利福昔明
环丙沙星
细菌性肠道感染
成本-效果分析
Evidence - based medicine
Rifaximin
Ciprofloxacin
Bacterial intestinal infection
Cost - effectivenessanalysis
